The U.S. Food and Drug Administration has issued a Class I recall for Erbe USA’s flexible cryoprobes due to reports of device rupture during activation that could cause serious injury to patients. The recall affects cryoprobes used in ear, nose, and throat procedures, with potential complications including permanent hearing loss and severe burns.
FDA Medical Device Recall Classifications
Severity levels based on health risk assessment, 2024
Source: FDA, 2024 | Georgian Medical Journal News
Device Rupture Creates Multiple Safety Hazards
The recalled Erbe flexible cryoprobes may rupture during normal activation, releasing pressurized gas and creating immediate safety risks for patients undergoing ENT procedures. According to the FDA safety communication, the rupture can cause hearing loss, tinnitus, physical injury from device fragments, or burns from escaping cryogenic materials.
Healthcare providers have been advised to immediately discontinue use of the affected devices and return them to Erbe USA. The FDA’s rapid response reflects the serious nature of potential complications, particularly in delicate ENT surgical environments where precision instruments are critical for patient safety.
Immediate Action Required for Healthcare Facilities
Medical facilities using Erbe cryoprobes must identify affected devices in their inventory and remove them from service immediately. The FDA guidance emphasizes that continued use poses unacceptable risks to patient safety, particularly for procedures involving sensitive anatomical structures in the ear and throat.
Healthcare providers should notify patients who recently underwent procedures with these devices about potential delayed complications. The recall represents part of broader efforts by regulators to enhance medical device safety oversight and rapid response to emerging safety signals.
Class I recalls indicate there is a reasonable probability that use of or exposure to the violative product will cause serious adverse health consequences or death
— FDA Center for Devices and Radiological Health (FDA Recall Guidelines, 2024)
Key takeaways
- Erbe flexible cryoprobes subject to Class I FDA recall due to rupture risk during activation
- Potential complications include hearing loss, tinnitus, burns, and physical injury from device fragments
- Healthcare facilities must immediately discontinue use and return affected devices to manufacturer
Frequently asked questions
What should patients do if they recently had a procedure with an Erbe cryoprobe?
Patients should contact their healthcare provider if they experience new hearing problems, persistent ringing in ears, or unusual pain following recent ENT procedures. While serious complications are possible, not all patients will be affected.
How can healthcare facilities identify recalled devices?
The FDA recall notice provides specific model numbers and lot information for affected Erbe flexible cryoprobes. Facilities should cross-reference their device inventory against the official recall list and immediately quarantine any matching devices.
What alternatives exist for cryotherapy procedures?
Healthcare providers should consult with medical device suppliers about alternative cryoprobe systems that are not subject to recall. Treatment decisions should prioritize patient safety while maintaining access to necessary ENT interventions.
The Erbe cryoprobe recall highlights the importance of robust post-market surveillance for medical devices, particularly those used in sensitive surgical applications. As healthcare systems implement the recall, attention will focus on preventing similar safety issues through enhanced device testing and monitoring protocols.
Source: Cryoprobe Recall: Erbe USA Removes Flexible Cryoprobes
Was this article helpful?
Related Coverage
